Výsledky vyhledávání

Winter maintenance—how to avert the emergency

Autor: J. D. Kent

Publikováno v: Proceedings of the Institution of Civil Engineers - Municipal Engineer. 151:265-270

This paper looks at two case studies where winter emergencies are averted by early closure of the road to traffic, and then considers whether these principles are relevant in a wider context. The paper questions whether the public attitude towards tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e36323970fe89949106dbd2d075bef38
https://doi.org/10.1680/muen.2002.151.4.265

Zobrazit plný text záznamu

Identification and regulation of protein kinase C-delta in human neutrophils

Autor: J D Kent, S Sergeant, D J Burns, L C McPhail

Publikováno v: The Journal of Immunology. 157:4641-4647

The intracellular mechanisms that regulate the function of human neutrophils are not well understood. Receptor-initiated signaling events result in the production of several second messengers (e.g., Ca2+, diacylglycerol, phosphatidic acid, and arachi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b3bd6577f8a2444807b84321a4966110
https://doi.org/10.4049/jimmunol.157.10.4641

Zobrazit plný text záznamu

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy

Autor: S, Lichtiger, D G, Binion, D C, Wolf, D H, Present, A G, Bensimon, E, Wu, A P, Yu, A T, Cardoso, J, Chao, P M, Mulani, K G, Lomax, J D, Kent

Publikováno v: Alimentary pharmacologytherapeutics. 32(10)

Adalimumab induces and maintains remission in adults with Crohn's disease.To evaluate safety, fistula healing, quality of life and work productivity in adalimumab-treated patients who failed infliximab, including primary nonresponders.After a ≥8-we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7db4605410b27fc7511624a9562fddcd
https://pubmed.ncbi.nlm.nih.gov/20955442

Zobrazit plný text záznamu

Plný text ve formátu HTML

Adalimumab for the treatment of fistulas in patients with Crohn's disease

Autor: J-F, Colombel, D A, Schwartz, W J, Sandborn, M A, Kamm, G, D'Haens, P, Rutgeerts, R, Enns, R, Panaccione, S, Schreiber, J, Li, J D, Kent, K G, Lomax, P F, Pollack

Publikováno v: Gut
Gut, 58(7), 940-948. BMJ Publishing Group

Objective: To evaluate the efficacy of adalimumab in the healing of draining fistulas in patients with active Crohn’s disease (CD). Design: A phase III, multicentre, randomised, double-blind, placebo controlled study with an open-label extension wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0db876219d454b8926198d972788ade6
https://pubmed.ncbi.nlm.nih.gov/19201775

Zobrazit plný text záznamu

Effect of diabetes and insulin treatment of diabetic rats on total RNA, poly(A)+ RNA, and mRNA in skeletal muscle

Autor: Leonard S. Jefferson, J. D. Kent, Scot R. Kimball

Publikováno v: American Journal of Physiology-Cell Physiology. 260:C409-C416

We have assessed the time course of alterations in several biochemical parameters and expression of specific mRNAs in gastrocnemius muscle following both the induction of diabetes and the administration of insulin to diabetic rats. Muscle mass, total

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2652f1cd9a6cb552790aa62dcb5af88
https://doi.org/10.1152/ajpcell.1991.260.3.c409

Zobrazit plný text záznamu

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

Autor: Remo Panaccione, Ju Li, Robert Enns, Paul F. Pollack, Marie R. Rosenfeld, Stephen B. Hanauer, Paul Rutgeerts, J. D. Kent, Jean-Frederic Colombel, Geert R. D'Haens, William J. Sandborn

Publikováno v: Annals of internal medicine, 146(12), 829-838. American College of Physicians

BACKGROUND Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c37bbb2fd46525e34ad96e9755fc303
https://pure.amc.nl/en/publications/adalimumab-induction-therapy-for-crohn-disease-previously-treated-with-infliximab-a-randomized-trial(1ad58a64-105f-4e21-ab02-69e07e5b1361).html

Zobrazit plný text záznamu

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Autor: Stephen B. Hanauer, Paul F. Pollack, Ju Li, Remo Panaccione, William J. Sandborn, Robert Enns, Paul Rutgeerts, Stefan Schreiber, Dan Byczkowski, Jean-Frederic Colombel, J. D. Kent

Publikováno v: Gastroenterology. 132(1)

Background & Aims: This study evaluated the efficacy and safety of adalimumab, a fully human, anti‐tumor necrosis factor monoclonal antibody administered subcutaneously, in the maintenance of response and remission in patients with moderate to seve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc321ce8976ab2a3baaf8c5e06889c8e
https://pubmed.ncbi.nlm.nih.gov/18223389

Zobrazit plný text záznamu

Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib

Autor: J L, Goldstein, G M, Eisen, N, Agrawal, W F, Stenson, J D, Kent, K M, Verburg

Publikováno v: Alimentary pharmacologytherapeutics. 20(5)

In a predefined analysis, data were pooled from eight blinded, randomized, controlled trials, and separately from three long-term, open-label trials to determine the rate of upper gastrointestinal ulcer complications with the cyclo-oxygenase-2 select

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9b370cd3757241acd07eb23ac52882fc
https://pubmed.ncbi.nlm.nih.gov/15339324

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání